KB-1202

Girentuximab

Background

Girentuximab is a humanized monoclonal antibody that specifically targets CAIX, a protein highly expressed in renal cell carcinoma but expressed at low levels in normal tissues. By binding to CAIX, Girentuximab can recognize and attack tumor cells, inhibiting their growth and spread. The mechanism of action of Girentuximab primarily involves direct inhibition of tumor cell proliferation and induction of immune responses. It can block tumor cell growth signaling by binding to CAIX and induce cell apoptosis. In addition, Girentuximab can activate the immune system, promoting immune clearance of tumor cells.

Specifications

Catalog Number:
KB-1202
Cell Line Name:
Girentuximab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
CAIX
Species Reactivity:
Human
Application:
FACS
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | FACS

References

1.Constantijn H J ,Muselaers, Alexander B ,et al.Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab.[J].Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014.DOI:10.2967/jnumed.114.137356. 2. Divgi C R , Uzzo R G , Gatsonis C ,et al.Positron Emission Tomography/Computed Tomography Identification of Clear Cell Renal Cell Carcinoma: Results From the REDECT Trial[J].Journal of Clinical Oncology, 2013.DOI:10.1200/jco.2011.41.2445.
Please enable JavaScript in your browser to complete this form.